SBUX
27
-17
LUV
48
-2
USB
39
2
VRSK
59
21
MKC
41
-7
OMC
58
3
CCL
33
-6
DOW
46
2
SRCL
34
-2
MTB
52
3
F
54
2
MCHP
55
-4
BF.B
50
-3
EXPE
56
-3
JCI
38
-12
HBAN
54
3
MDLZ
65
-4
MET
43
6
PLD
38
-7
LEG
16
-15
SBUX
27
-17
LUV
48
-2
USB
39
2
VRSK
59
21
MKC
41
-7
OMC
58
3
CCL
33
-6
DOW
46
2
SRCL
34
-2
MTB
52
3
F
54
2
MCHP
55
-4
BF.B
50
-3
EXPE
56
-3
JCI
38
-12
HBAN
54
3
MDLZ
65
-4
MET
43
6
PLD
38
-7
LEG
16
-15
Financhill
Back

Syros Pharmaceuticals 10K Form

Buy
84

SYRS
Syros Pharmaceuticals

Last Price:
5.45
Seasonality Move:
6.39%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SYRS News And Ratings

See the #1 stock for the next 7 days that we like better than SYRS

SYRS Financial Statistics

Sales & Book Value

Annual Sales: $9.94M
Cash Flow: $-18.6M
Price / Cash Flow: 0
Annual Sales: $0.63
Price / Book: 8.64

Profitability

EPS (TTM): -5.80000
Net Income (TTM): $-164.57M
Gross Margin: --
Return on Equity: -228.14%
Return on Assets: -86.91%

Syros Pharmaceuticals Earnings Forecast

Key Syros Pharmaceuticals Financial Ratios

  • The Research & Development expenses have been 1,088.50% of Revenue.
  • The Interest Expense is -3.12% of Operating Income.
  • The Net Earning history of SYRS is -1,656.34% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 8 years.

Syros Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SYRS
CUSIP: 87184Q
Website: syros.com

Debt

Debt-to-Equity Ratio: 2.47
Current Ratio: 3.95
Quick Ratio: 3.8

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

SYRS Technical Analysis vs Fundamental Analysis

Buy
84
Syros Pharmaceuticals (SYRS) is a Buy

Is Syros Pharmaceuticals a Buy or a Sell?